文献速递肝胆胰外科

肝癌门静脉栓塞后疾病进展是否构成后续肝切除的禁忌证

Is disease progression a contraindication for the strategy of portal vein embolization followed by hepatectomy for hepatocellular carcinoma?
PubMed 文献 · Surgery · 2018-11-19

本研究纳入57例接受门静脉栓塞后行肝切除的肝细胞癌患者,评估其长期肿瘤学结局及栓塞后疾病进展对生存的影响。结果显示肝切除后5年总生存率和无病生存率分别为74.5%和31.7%,门静脉栓塞后疾病进展(包括肿瘤大小、数目、标志物增加)不影响总生存,仅肿瘤数目增加在单因素分析中显著降低无病生存率。结论认为若计划肝切除能完成,栓塞后疾病进展不构成禁忌。

要点

  • 门静脉栓塞后疾病进展不影响肝细胞癌患者肝切除后的长期总生存。
  • 仅肿瘤数目增加在单因素分析中显著降低无病生存率。
  • 若计划肝切除能完成,栓塞后疾病进展不构成禁忌。

核心结论

  • 门静脉栓塞后疾病进展不影响肝细胞癌患者长期生存,若计划肝切除能完成则不构成禁忌。

研究设计与样本

  • 回顾性研究纳入2000至2016年间接受门静脉栓塞后肝切除的57例肝细胞癌患者。

主要发现

  • 肝切除后5年总生存率和无病生存率分别为74.5%和31.7%。
  • 门静脉栓塞后肿瘤大小增加、肿瘤数目增加、甲胎蛋白增加、岩藻糖基化甲胎蛋白增加和des-γ-羧基凝血酶原增加分别见于22.8%、14.0%、29.8%、19.3%和47.4%的患者。
  • 单因素分析仅肿瘤数目增加显著降低肝切除后无病生存率,所有变量均不影响总生存。

临床怎么用

  • 对门静脉栓塞后出现疾病进展但计划肝切除可完成的肝细胞癌患者,不应仅因进展而放弃手术。

局限性

  • 回顾性研究,样本量57例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Portal vein embolization has been used worldwide to induce hypertrophy of the future liver remnant and to reduce the risk of hepatic insufficiency and death after major hepatectomy. However, whether disease progression after portal vein embolization can affect long-term oncologic outcomes in patients with hepatocellular carcinoma is uncertain. METHODS: From a total of 107 patients who underwent portal vein embolization and subsequent hepatectomy between 2000 and 2016, 57 patients with hepatocellular carcinoma were enrolled. We evaluated their long-term oncologic outcomes and investigated whether the disease progression between portal vein embolization and subsequent hepatectomy affected survival. RESULTS: The 5-year overall survival and disease-free survival after hepatectomy were 74.5% and 31.7%, respectively. Multivariate analyses revealed that tumor number before hepatectomy ≥3 (hazard ratio 3.59, P = .019), des-γ-carboxy prothrombin >200 mAU/mL (hazard ratio 3.36, P = .045), and red blood cell transfusion (hazard ratio 11.03, P = .0008) were independent prognostic factors for overall survival. Male sex (hazard ratio 3.74, P = .029), bilobar tumor distribution (hazard ratio 3.65, P = .004), and red blood cell transfusion (hazard ratio 6.22, P = .0026) were independent prognostic factors for disease-free survival. Disease progressions after portal vein embolization, including increases in tumor size, tumor number, α-fetoprotein, lens culinaris agglutinin-reactive fraction of α-fetoprotein, and des-γ-carboxy prothrombin, were observed in 22.8%, 14.0%, 29.8%, 19.3%, and 47.4% of patients, respectively. Only an increase of tumor number significantly decreased the disease-free survival rate after hepatectomy in a univariate analysis, and none of the variables affected overall survival. CONCLUSION: Disease progression after portal vein embolization did not affect long-term survival in patients with hepatocellular carcinoma if the planned subsequent hepatectomy could be completed.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Imai K, Yamashita YI, Nakao Y, et al. Is disease progression a contraindication for the strategy of portal vein embolization followed by hepatectomy for hepatocellular carcinoma? Surgery. 2018. PMID: 30467039. doi:10.1016/j.surg.2018.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。